BACKGROUND AND PURPOSE: PPAR-γ has been reported to be a protective regulator in ischaemia/reperfusion (I/R) injury. The receptor for advanced glycation end-products (RAGE) plays a major role in the innate immune response, and its expression is associated with PPAR-γ activation. Several angiotensin receptor blockers possess partial agonist activities towards PPAR-γ. Therefore, this study investigated the action of losartan, particularly with regard to PPAR-γ activation and RAGE signalling pathways during hepatic I/R. EXPERIMENTAL APPROACH: Mice were subjected to 60 min of ischaemia followed by 6 h of reperfusion. Losartan (0.1, 1, 3 and 10 mg · kg⁻¹) was administered 1 h prior to ischaemia and immediately before reperfusion. GW9662, a PPAR-γ antagonist, was administered 30 min prior to first pretreatment with losartan. KEY RESULTS: Losartan enhanced the DNA-binding activity of PPAR-γ in I/R. Losartan attenuated the increased serum alanine aminotransferase activity, TNF-α and IL-6 levels, and nuclear concentrations of NF-κB in I/R. GW9662 reversed these beneficial effects. Losartan caused a decrease in apoptosis as assessed by TUNEL assay, in release of cytochrome c and in cleavage of caspase-3, and these effects were abolished by GW9662 administration. Losartan attenuated not only I/R-induced RAGE overexpression, but also its downstream early growth response protein-1-dependent macrophage inflammatory protein 2 level; phosphorylation of p38, ERK and JNK; and subsequent c-Jun phosphorylation. GW9662 reversed these effects of losartan administration. CONCLUSIONS AND IMPLICATIONS: Our findings suggest that losartan ameliorates I/R-induced liver damage through PPAR-γ activation and down-regulation of the RAGE signalling pathway.
BACKGROUND AND PURPOSE: PPAR-γ has been reported to be a protective regulator in ischaemia/reperfusion (I/R) injury. The receptor for advanced glycation end-products (RAGE) plays a major role in the innate immune response, and its expression is associated with PPAR-γ activation. Several angiotensin receptor blockers possess partial agonist activities towards PPAR-γ. Therefore, this study investigated the action of losartan, particularly with regard to PPAR-γ activation and RAGE signalling pathways during hepatic I/R. EXPERIMENTAL APPROACH: Mice were subjected to 60 min of ischaemia followed by 6 h of reperfusion. Losartan (0.1, 1, 3 and 10 mg · kg⁻¹) was administered 1 h prior to ischaemia and immediately before reperfusion. GW9662, a PPAR-γ antagonist, was administered 30 min prior to first pretreatment with losartan. KEY RESULTS:Losartan enhanced the DNA-binding activity of PPAR-γ in I/R. Losartan attenuated the increased serum alanine aminotransferase activity, TNF-α and IL-6 levels, and nuclear concentrations of NF-κB in I/R. GW9662 reversed these beneficial effects. Losartan caused a decrease in apoptosis as assessed by TUNEL assay, in release of cytochrome c and in cleavage of caspase-3, and these effects were abolished by GW9662 administration. Losartan attenuated not only I/R-induced RAGE overexpression, but also its downstream early growth response protein-1-dependent macrophage inflammatory protein 2 level; phosphorylation of p38, ERK and JNK; and subsequent c-Jun phosphorylation. GW9662 reversed these effects of losartan administration. CONCLUSIONS AND IMPLICATIONS: Our findings suggest that losartan ameliorates I/R-induced liver damage through PPAR-γ activation and down-regulation of the RAGE signalling pathway.
Authors: Kai Wang; Zhongmin Zhou; Ming Zhang; Liming Fan; Farhad Forudi; Xiaorong Zhou; Wu Qu; A Michael Lincoff; Ann Marie Schmidt; Eric J Topol; Marc S Penn Journal: J Pharmacol Exp Ther Date: 2005-12-20 Impact factor: 4.030
Authors: Sydney C W Tang; Joseph C K Leung; Loretta Y Y Chan; Anita W L Tsang; Kar Neng Lai Journal: J Am Soc Nephrol Date: 2006-05-10 Impact factor: 10.121
Authors: Thomas Shin; Satoshi Kuboki; Nadine Huber; Thorsten Eismann; Elizabeth Galloway; Rebecca Schuster; John Blanchard; Timothy A Pritts; Alex B Lentsch Journal: J Surg Res Date: 2008-03-13 Impact factor: 2.192
Authors: Jong Sun Chang; Thoralf Wendt; Wu Qu; Linghua Kong; Yu Shan Zou; Ann Marie Schmidt; Shi-Fang Yan Journal: Circ Res Date: 2008-03-06 Impact factor: 17.367
Authors: Juan Wang; Tao Pang; Roman Hafko; Julius Benicky; Enrique Sanchez-Lemus; Juan M Saavedra Journal: Neuropharmacology Date: 2013-12-04 Impact factor: 5.250
Authors: Marco Pahor; Stephen D Anton; Daniel P Beavers; Jane A Cauley; Roger A Fielding; Stephen B Kritchevsky; Christiaan Leeuwenburgh; Kristina H Lewis; Christine K Liu; Laura C Lovato; Jane Lu; Todd M Manini; Mary M McDermott; Michael E Miller; Anne B Newman; Barbara Radziszewska; Cynthia L Stowe; Russell P Tracy; Michael P Walkup; Samuel S Wu; Walter T Ambrosius Journal: J Gerontol A Biol Sci Med Sci Date: 2019-09-15 Impact factor: 6.053
Authors: Min Yang; Daniel J Antoine; James L Weemhoff; Rosalind E Jenkins; Anwar Farhood; B Kevin Park; Hartmut Jaeschke Journal: Liver Transpl Date: 2014-11 Impact factor: 5.799